TY - JOUR
T1 - Challenging clinical scenarios for therapeutic anticoagulation
T2 - A practical approach
AU - Martens, Kylee L.
AU - Dekker, Simone E.
AU - Crowe, Megan
AU - DeLoughery, Thomas G.
AU - Shatzel, Joseph J.
N1 - Funding Information:
Dr. Shatzel is supported by the National Institutes of Health , National Heart, Lung, and Blood Institute ( HL151367 ).
Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/10
Y1 - 2022/10
N2 - Therapeutic anticoagulation remains a fundamental backbone in the treatment and prevention of venous thromboembolism. However, while modern therapies are increasingly safe, anticoagulation is not without risks, particularly in those at high risk for or with recent bleeding. When weighing concurrent risks and benefits in each challenging clinical scenario, an individualized assessment of the risk and acuity of bleeding should be balanced by the indication for anticoagulation. Addressing modifiable risk factors and routine re-evaluation of any changes in this balance is critical. This review outlines available data and current guidelines for the management of anticoagulation in high-risk populations, including those with thrombocytopenia, elderly and high-fall risk, inherited bleeding disorders, and in acute coronary syndrome. We also examine management after clinically significant bleeding episodes, including intracranial hemorrhage, gastrointestinal bleeding, hemoptysis, retroperitoneal bleeding, hematuria, and abnormal uterine bleeding. The aim is to provide a comprehensive review of available literature to guide clinicians in providing optimal, safe, and individualized care for patients in these challenging scenarios.
AB - Therapeutic anticoagulation remains a fundamental backbone in the treatment and prevention of venous thromboembolism. However, while modern therapies are increasingly safe, anticoagulation is not without risks, particularly in those at high risk for or with recent bleeding. When weighing concurrent risks and benefits in each challenging clinical scenario, an individualized assessment of the risk and acuity of bleeding should be balanced by the indication for anticoagulation. Addressing modifiable risk factors and routine re-evaluation of any changes in this balance is critical. This review outlines available data and current guidelines for the management of anticoagulation in high-risk populations, including those with thrombocytopenia, elderly and high-fall risk, inherited bleeding disorders, and in acute coronary syndrome. We also examine management after clinically significant bleeding episodes, including intracranial hemorrhage, gastrointestinal bleeding, hemoptysis, retroperitoneal bleeding, hematuria, and abnormal uterine bleeding. The aim is to provide a comprehensive review of available literature to guide clinicians in providing optimal, safe, and individualized care for patients in these challenging scenarios.
KW - Anticoagulation management
KW - Thrombosis and hemostasis
UR - http://www.scopus.com/inward/record.url?scp=85136454635&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136454635&partnerID=8YFLogxK
U2 - 10.1016/j.thromres.2022.08.015
DO - 10.1016/j.thromres.2022.08.015
M3 - Review article
C2 - 36027629
AN - SCOPUS:85136454635
SN - 0049-3848
VL - 218
SP - 72
EP - 82
JO - Thrombosis Research
JF - Thrombosis Research
ER -